Ipsen: Licensing agreement for IB-1001 with Cangene

BUY, Fair Value EUR29 (+12%)

News published on February Wednesday 6, 2013
Share on
Following an agreement with Baxter for OBI-1, Ipsen announces today an agreement for IB-1001 with Cangene Corporation for USD5.9m upfront and USD50m potential milestones as well as double digits royalties.

Full report available to subscribers
Please contact marketing@bryangarnier.fr

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities